Picture of Zosano Pharma logo

ZSAN — Zosano Pharma Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-13.05%
3m-69.34%
6m-88.63%
1yr-91.55%
Volume Change (%)
10d/3m-70.75%
Price vs... (%)
52w High-94.39%
50d MA-49.03%
200d MA-86.42%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-330.19%
Return on Equity-192.97%
Operating Margin-8375.11%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Zosano Pharma EPS forecast chart

Profile Summary

Zosano Pharma Corporation is a clinical-stage biopharmaceutical company. The Company is focused on providing rapid systemic administration of therapeutics and other bioactive molecules to patients using its transdermal microneedle system (the System). Its System is designed to facilitate rapid drug absorption into the bloodstream, and to provide an improved pharmacokinetic (PK) profile compared to original dosage forms. The System consists of a three cm square to six cm square array of titanium microneedles approximately 200-350 microns in length, coated with a hydrophilic formulation of drug, mounted on an adhesive patch. It is focused on development of its lead product candidate, M207, a formulation of zolmitriptan, which is used as an acute treatment for migraine. Its zolmitriptan formulation is delivered utilizing its system. M207 is designed to provide rapid absorption of zolmitriptan into the bloodstream without dependence on the gastrointestinal (GI) tract.

Directors

Last Annual
December 31st, 2021
Last Interim
March 31st, 2022
Incorporated
January 26th, 2012
Public Since
January 27th, 2015
No. of Shareholders
13
No. of Employees
40
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
4,902,260

ZSAN Share Price Performance

Upcoming Events for ZSAN

Zosano Pharma Corp Annual Shareholders Meeting

Q2 2022 Zosano Pharma Corp Earnings Release

Q3 2022 Zosano Pharma Corp Earnings Release

Similar to ZSAN

Picture of 180 Life Sciences logo

180 Life Sciences

us flag iconNASDAQ Capital Market

Picture of 9 Meters Biopharma logo

9 Meters Biopharma

us flag iconNASDAQ Capital Market

Picture of Abeona Therapeutics logo

Abeona Therapeutics

us flag iconNASDAQ Capital Market

Picture of ABVC Biopharma logo

ABVC Biopharma

us flag iconNASDAQ Capital Market

Picture of Acer Therapeutics logo

Acer Therapeutics

us flag iconNASDAQ Capital Market

FAQ

Or unlock with your email

Or unlock with your email